J Clin Invest. 1986;77(1):157-164. https://doi.org/10.1172/JCI112270. Impaired platelet aggregation, normal shape change, and agglutination and normal ATP secretion and thromboxane synthesis in response to high concentrations of thrombin or arachidonic acid were found in a patient with multiple myeloma and hemorrhagic tendency. The purified IgG1 kappa or its F(ab1)2 fragments induced similar changes when added in vitro to platelet-rich plasma from normal subjects. In addition, the paraprotein inhibited adhesion to glass microbeads, fibrin clot retraction, and binding of radiolabeled fibrinogen or von Willebrand factor to platelets exposed to thrombin or arachidonic acid without affecting intraplatelet levels of cAMP. The radiolabeled para-protein bound to an average of 35,000 sites on normal platelets but it bound to less than 2,000 sites on the platelets from a patient with Glanzmann's thrombasthenia. Immunoprecipitation studies showed that the platelet antigen identified by the paraprotein was the glycoprotein IIIa. Furthermore, binding of radiolabeled prostaglandin E1 (PGE1) to resting platelets as well as binding of von Willebrand factor to platelets stimulated with ristocetin were entirely normal in the presence of patient's inhibitor. These studies indicate that bleeding occurring in dysproteinemia may be the result of a specific interaction of monoclonal paraproteins with platelets. In addition, our data support the concept that the interaction of fibrinogen and/or von Willebrand factor with the platelet glycoprotein IIb-IIIa complex is essential for effective hemostasis.
Introduction
Patients with dysproteinemia and hemorrhagic tendency often have hemostatic abnormalities and circulating monoclonal paraproteins (1) . Most of these paraproteins have been identified as immunoglobulin inhibitors of phospholipids (2) or major components ofthe coagulation cascade (3-7); however, inhibitors of platelet function have also been reported (8-1 1). Platelet abnormalities in dysproteinemia include impaired platelet aggre-gation and adhesiveness and reduced Factor III availability and are thought to occur as a consequence of nonspecific adherence ofthe inhibitor to the platelet surface (1, 8-1 1) . We have studied a patient with multiple myeloma, marked hemorrhagic tendency, and in vitro platelet abnormalities, whose monoclonal paraprotein induces a thrombasthenic-like state in normal platelets. We report here that inhibition of platelet function by this antibody is the result of a specific immunologic reaction with the glycoprotein I11a (GPIIIa)'.
Methods
Preswollen microgranular DEAE cellulose was from Whatman, Inc., Clifton, NJ. Firefly luciferase and luciferin (Chronolume 395) were purchased from Chrono-Log Corp., Havertown, PA; disodium EDTA and 2-dithiothreitol (DTT) were obtained from Fisher Scientific Co., Pittsburgh, PA. EDTA was prepared as a 100-mM stock solution in distilled water (pH adjusted to 7.4 and 8.7 with NaOH). Pepsin (2,500 U/mg) was from Worthington Biochemical, Freehold, NJ; Nonidet P40 was obtained from Particle Data Inc., Elmhurst, IL and Triton X-100 was obtained from Amersham Corp., Arlington Heights, IL. Acrylamide, N-N-methylene-bis-acrylamide, Coomassie Brilliant Blue R250, and molecular weight standards were from Bio-Rad Laboratories, Richmond, CA; bovine serum albumin (Pentex fraction V) was from Miles Laboratories, Inc., Elkhart, IN. Hirudin, phenylmethylsulphonyl fluoride (PMSF), ADP, ATP, sodium dodecyl sulfate (SDS), Hepes, lactoper- oxidase (70-100 U/mg protein) agar, and prostaglandin El (PGE,) were from Sigma Chemical Co., St. Louis, MO. Agar and SDS were dissolved in distilled water immediately before each series of experiments; ADP, ATP, and hirudin were dissolved in distilled water and stored in small aliquots at -20°C; PGE, was dissolved in ethyl alcohol and stored at -20°C. Thrombin (Parke Davis and Co., Detroit, MI) was dissolved in distilled water and stored in small aliquots at -70°C. Protein A-Sepharose CL 4B and cyanogen bromide-activated Sepharose were from Pharmacia Fine Chemicals, Piscataway, NJ. Arachidonic acid (AA) and calcium ionophore A23187 were kindly provided by Dr After centrifugation at 2,000 g for 6 min at 40C in a centrifuge (J-6B; Beckman Instruments, Inc.), the platelets were resuspended in a volume of buffer (0. 14 M NaCl, 20 mM Tris, 5 mM glucose, and 1 mM EDTA, pH 7.4) equal to that of the discarded plasma, centrifuged at 900 g for 6 min at room temperature, and resuspended at counts in the range of 1-5 X 108/ml in a Tyrode's buffer (0.14 M NaCl, 2.7 mM KC1, 1 mM CaC12, 12 mM NaHCO3, and 0.4 mM NaH2PO4) containing 5 mM glucose, 3.5 mg/ml bovine serum albumin, and 10 mM Hepes, pH 7.4 . Platelet counts were determined by phase-contrast microscopy. When trace amounts of '251I-fibrinogen or '251I-vWF were added to the PRP, >99% of these proteins were removed by the washing procedure. Further properties of platelets washed and resuspended in this manner have been previously reported (12) . Suspensions of washed platelets showed full aggregation only in the presence of 600 nM (final) of added fibrinogen. Therefore, this concentration of fibrinogen was used in all the aggrgation studies in which washed platelets were employed. For both PRP and platelets in suspension, aggregation was measured as percent light transmittance 3 min after the addition of the stimulus in on ELVI 840 aggregometer (Elvi-Logos, Milano, Italy). Platelet retention on glass microbeads was determined using a pump system (Adeplat "S"; MasciaBrunelli, Milano, Italy). For this study, 5-7 ml of blood were drawn from the antecubital vein through a 19-gauge butterfly infusion set into a series of 20 ml Terumo syringes containing heparin (50 M1 of a 1-U/ ml solution) or heparin plus patient's paraprotein (50 Mg/ml). After gentle mixing, the syringes were placed in the infusion pump and adhesion to glass microbeads was determined and quantified according to the manufacturer's recommendations.
Purification of patient's paraprotein. Electrophorectic and immunoelectrophoretic studies showed the presence of a monoclonal IgG, kappa peak in the serum of the patient. For further studies, patient's paraprotein was first isolated by nitrocellulose paper chromatography, then eluted with phosphate buffer, 0.015 M, pH 7.4, and dialyzed overnight at 4°C and finally applied to a 2 X 20-cm DEAE column preequilibrated with the same buffer. Elution was performed with 300-400 ml of phosphate buffer, pH 7.4, in a gradient from 0.015 to 0.30 M, as recommended by Fahey and Terry (14) . Patient's paraprotein eluted from the column at low phosphate molarity (0.015-0.060). At this low molarity only immunoglobulins of the G type are eluted (14) . Confirmation of the purity of the preparation was obtained when the eluted paraprotein was incubated overnight at 4°C in polystyrene micro-wells and the coated solid phase was allowed to react with monoclonal mouse immunoglobulins against human IgG,, IgG3, and IgG4. After 3 h of incubation at room temperature, purified goat anti-mouse F(ab')2 fragments coupled with alkaline phosphatase were added and, after an additional 3 h incubation at room temperature, p-nitrophenyl-phosphate was added. The reaction was stopped 30 min later by adding 3 N NaOH. These studies showed a strong colored reaction only in the wells in which anti IgG, antibodies had been added. IgG, paraproteins from the sera of two other patients with multiple myeloma and no bleeding tendency were purified and characterized in a similar fashion and used as a control throughout. Immunoglobulins G from the sera of normal subjects were purified according to Fahey and Terry (14) and IgG, subclasses were separated from IgG2 in a protein A-Sepharose column according to Duhamel et al. (15) . No quantitative or qualitative differences in the results were found when the paraproteins were purified as reported above or isolated from the serum on a protein A-Sepharose column (15) . F(ab')2 preparation. Purified paraprotein was dialyzed overnight at 4VC against a 0.2-M sodium acetate solution pH 4.1 after which freshly prepared pepsin (1 mg/ml) was added in an amount equal to 2% of the antibody's weight and the solution was incubated at 370C. 18 h later, digestion was stopped by centrifuging the solution at 4,000 rpm for 10 min at 4VC, neutralizing the supernatant with NaOH 1 N, and dialyzing against citrate-phosphate buffer, pH 7. Residual Fc fragments and intact immunoglobulins were removed on a protein A-Sepharose column. Both patient's paraprotein and its F(ab')2 fragments showed a single band of 160,000 mol wt and 105,000 mol wt, respectively, when electrophoresed in a 7.5% SDS-polyacrylamide gel (16) .
Paraprotein iodination and binding to human platelets. Intact paraprotein as well as its F(ab')2 fragments were labeled by the iodine monochloride method as previously described for murine monoclonal antibodies (17) . Specific activities of these preparations were 4.3 X 104 cpm/ MAg for the intact paraprotein and 3.3 X 104 cpm/pg for F(ab')2 fragments.
For time-dependent binding studies, aliquots (3 ml) ofunstirred platelets
(1-5 X 10' platelets/ml) in PRP or in suspensions of washed cells were incubated at room temperature (22°C) with AA (10 ,M) or microliter amounts of buffer. After a 3-min incubation, labeled paraprotein was added at a final concentration of 10 stg/ml and, at intervals between I and 15 min, 0.4 ml of the suspension was removed and layered onto 50
Ml of silicone oil in a 0.5 ml of micro-Eppendorf tube. Free and plateletbound ligand were separated by centrifugation for 2 min at 12,000 g in an Eppendorf centrifuge and counted in a Beckman DP 5,500 gainmacounter (DP 5,500; Beckman Instruments, Inc.). For dose-response studies, 500-Ml aliquots of unstirred platelets were incubated with 10 IM AA or equal volumes ofbuffer for 3 min, after which labeled paraprotein was added in final concentrations between I and 128 ,g/ml. Binding was determined 1 min later. Specific binding was calculated by subtracting the binding measured in the presence of a 20-fold excess of unlabeled paraprotein from the total. This latter nonspecific binding represented 1.73±0.07% of the total radioactivity bound. Binding was not corrected for the radioactivity trapped as determined by adding trace amounts of '4C-inulin. Trapping never exceeded 0.5% of the total bound. Effect ofpatient's paraprotein on aggregation, secretion, andfibrinogen and vWF binding to platelets. Increasing amounts (from 1 to 128 Ug/ ml, final) of patient's paraprotein or 500 Mg/ml of control antibodies were incubated with 0.5 ml PRP (or washed platelets in suspension) that had been stirring at 1,000 rpm for 1 min at 37°C. After a further minute of stirring the agents were added and 1 min later, buffer (or fibrinogen, 600 nM final) was added. In parallel, unlabeled patient's paraprotein, in concentrations ranging from 1 to 128 ug/ml, were incubated with platelet suspensions in the absence ofstirring at 22°C. After 1 min, the aggregating agent was added and after a further minute, '25I-fibrinogen (600 nM, final) or '251-vWF (20 Mg/ml, final) were added. Binding of the ligands was measured after 5 min for fibrinogen and after 45 min for vWF (12) . When thrombin was the stimulus employed to expose binding sites for fibrinogen, hirudin (0.1 U/ml) was used to prevent clotting and was added simultaneously with fibrinogen. In other studies, platelet suspensions (1-5 X 108/ml) were incubated at room temperature for 1 min with 50 Mg/ml of patient's paraprotein or buffer after which 10 mU/ml thrombin, 10 MM AA, or 1.5 mg/ml ristocetin were added. 3 min later, increasing concentrations of '251I-fibrinogen (from 37.5 to 1,200 nM final) or 125I-vWF (from 1.25 to 40 ug/ml) were added, and at appropriate time-intervals (5 min for fibrinogen and 45 min for vWF), free and platelet-bound ligands were separated in silicone oil and counted. When ristocetin was the stimulus, formaldehyde-fixed platelets were used.
Studies on specificity ofpatient's paraprotein. Patient's paraprotein specificity was determined as described in detail elsewhere for a murine monoclonal antibody (17 (16) . Molecular weight standards were run on each gel. Gels were run at 40 mA constant current until the front (visible as refractive index difference) reached the bottom of the gel. Running time was 4-5 h. Gels were then stained with Coomassie Blue, dried, autoradiographed, and identified after I wk of development at -70°C. The blue-stained bands of the molecular weight standards were used to determine the approximate relative molecular weight (Mr) of the bands recorded on the autoradiograms. In another series of studies 5 X I09 washed platelets were incubated at 4°C in a buffer containing 0.15 M NaCl, 0.02 M Tris, 2.5 mM EDTA, pH 7.4, 1 mM PMSF, 0.2 M DTT, and 1% Triton, pH 7.5. 15 min later, the solubilized platelet suspension was centrifuged at 40,000 g for 60 min at 4°C and the supernatant applied to a 1 X 4-cm column containing 5 mg of patient's paraprotein coupled to 4 ml of cyanogen-bromide-activated Sepharose. This column had been preequilibrated with the same buffer in which solubilized platelets were resuspended. After extensive washing of the column, the affinity-bound proteins were eluted with 5 ml of a 3% SDS solution, heated to 100°C for 3 min, and subjected to a 7.5% SDS polyacrylamide gel electrophoresis (16 Platelet aggregation and agglutination were measured as percent maximal light transmittance 3 min after the addition of the stimulus and adjusting the aggregometer so that PRP and platelet-poor plasma produced 10 and 90% light transmittance, respectively; TxB2 synthesis was measured by radioimmunoassay in aliquots of stirred (1,000 rpm) samples 3 min after the addition of the stimulus and expressed as pmol TxB2/3 x 108 platelets; secretion of ATP was determined in a lumi-aggregometer by using luciferin-luciferase reagent (50 ,l of a 10 mg/ml solution) and expressed as umol ATP secreted/10" platelets. The values reported for the patient are means±SEM of three determinations; those for controls are composite data from seven PRPs studied. A significant difference (P < 0.01) was always found when the data relative to the aggregation of platelets from the patient were compared with those from controls. In all the other determinations the P value was always >0.05.
or AA were within normal ranges. As with ADP, shape change in response to collagen was entirely normal (not shown). Platelet adhesion to glass microbeads was determined in an Adeplat "S" system employing blood freshly drawn into syringes containing heparin or heparin plus patient's paraprotein; fibrin clot retraction was calculated by relating the volume of serum extruded at 60 min to the total amount of the initial mixture (PRP + thrombin) and expressed as a percentage; methods employed for studying and measuring platelet aggregation, agglutination, TxB2 synthesis, and ATP secretion are given in the legend of Table I . Each value is the mean±SEM of composite data from seven PRPs studied. Addition of the antibody had no effect (P always > 0.05) on the agglutination of platelets in response to ristocetin as well as on the secretion of ATP and the synthesis of TxB2 in response to high concentrations of thrombin or AA. In all the other studies patient's paraprotein significantly affected platelet function (P always < 0.01).
with 5 mM EDTA for 5 min before the addition of A23 187 (50 gM). These data are similar to those obtained using platelets from thrombasthenic patients (12) and comparable to those obtained by incubating normal platelets with a murine monoclonal antibody to the glycoprotein lIb-IIla complex (GPIIb-IIIa) (19) and were interpreted to suggest that the aggregation of platelets may act to enhance secretion of nucleotides and TxB2 synthesis when low doses of agonists are used, whereas at higher doses secretion and TxB2 formation are largely independent of aggregation. Similar results were found when equimolar concentra- (19, 20) . The data reported are means±SEM of seven different PRP tested.
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fibrinogen binding was measured as a function of '25I-fibrinogen concentration employed. Analysis of the data by using double reciprocal plots was consistent with a noncompetitive inhibition of the binding by the paraprotein (Fig. 2) . Selectivity of the inhibition of fibrinogen binding by the paraprotein was then determined by evaluating the effects ofthe inhibitor on the binding of PGE, and vWF to platelets. The former was studied because a murine monoclonal antibody (B59.2) to the platelet receptor for fibrinogen does not affect the binding of this prostaglandin to resting platelets (unpublished observations of the authors); the latter was chosen since the presumed receptor for fibrinogen on the platelet surface is also one of the binding sites for vWF on these cells (13, 21, 22 Nonspecific binding never exceeded 15%. The data were then expressed in terms of double-reciprocal plot. Each point is the mean+SEM of four different platelet suspensions tested. Similar results were found when thrombin was the stimulus used.
the binding in response to 10 mU/ml thrombin or 10 ,M AA (Table III) . Similar results were found when higher concentrations of thrombin or AA (i.e., 40 mU/ml for thrombin and 40
MM for AA) were used. Concentrations of control paraproteins or normal IgG, as high as 500 ug/ml did not affect binding of fibrinogen or vWF in response to AA or thrombin (not shown).
Specificity ofpatient's paraprotein. The immunoprecipitate formed by the reaction of patient's paraprotein with radiolabeled platelet membrane glycoproteins was solubilized in 3% SDS, reduced with 0.2 M DTT, and autoradiographed. As shown in Fig. 3 A, the inhibitor precipitated very close bands (apparent Mr, 1 16 ,000) in the presence of Ca2+ (1 mM) or EDTA (10 mM, pH 7.4). These bands were not present in immunoprecipitates in which platelets from a thrombasthenic patient were used or in those in which platelets from normal donors were incubated with an IgG, paraprotein from a patient with multiple myeloma and no bleeding tendency. Specificity of patient's paraprotein was further confirmed in affinity chromatography studies. After reduction, two peptides of 120,000 apparent Mr and 1 10,000 apparent Mr were eluted in addition to a faint band of 65,000 M, comigrating with albumin and in some samples to another band of -40,000 M, comigrating with actin. These minor bands were not present in immunoprecipitates and did not interact with the paraprotein in immunblots (24 However, antibody activity has been clearly demonstrated for only a few of them (28) . The paraprotein that we have isolated from our patient has antibody activity biochemically and functionally comparable to that of an antibody isolated from a polytransfused thrombasthenic patient (29, 30) or from patients with immune thrombocytopenia (31, 32) . Much evidence has been accumulated to indicate that GPIIbIlla is the receptor for fibrinogen and vWF on platelets exposed to naturally occurring aggregating agents and that the interaction of fibrinogen and vWF with this complex is essential for effective hemostasis as well as for a variety of in vitro platelet functions (21) . Patients with Glanzmann's thrombasthenia have a bleeding tendency (21) and platelets from these patients lack GPIIb-IIIa (18, 21, 33) and exhibit negligible binding of fibrinogen after stimulation with ADP (30, (34) (35) (36) (37) and deficient binding of vWF when exposed to thrombin (22) . Estimates of the affinity indicate that normal platelets have~-39,000-50,000 binding sites for fibrinogen (12, 17, 19, 21, 34, 35 ), a figure comparable to the number of GPIIb-IIIa complexes identified on the surface of normal platelets by specific monoclonal antibodies (17, 19, (38) (39) (40) (41) . GPIIb-IIIa may form complexes with fibrinogen (42) , and murine monoclonal antibodies to GPIIb and/or IlIa inhibit aggregation as well as binding of fibrinogen or vWF to platelets (13, 17, 19, (38) (39) (40) . Screening tests (Table I) in platelets from this patient showed abnormalities comparable to those described in Glanzmann's thrombasthenia (21) . Most reports indicate that thrombasthenic platelets do not aggregate at all in response to collagen (21) . However, studies by several investigators showed that small aggregates are, in fact, produced (43) (44) (45) (46) . Similar results are also obtained after in vitro addition to normal platelets of a monoclonal antibody to GPIIb-IIIa complex (19) . It is unclear whether these aggregates are the result of platelet-platelet interactions or rather the adhesion of several platelets to collagen fibrils, which can simulate the appearance of an aggregate. The in vitro addition of purified paraprotein to normal platelets caused all the abnormalities observed in platelets from the patient and also impaired adhesion to glass beads, fibrin clot retraction, and binding of fibrinogen and vWF in response to thrombin or AA. Thus, it induced a thrombasthenic-like state in normal platelets. In addition, the paraprotein bound to normal platelets ( Fig. 1) but only negligibly to platelets from a thrombasthenic patient; it reacted with GPIIb-IIIa on immunoprecipitates as well as on an antibody-coupled affinity column and it only inhibited the binding to platelets of agonists whose receptor is known to be GPIIb-IIIa. The aggregation as well as the binding of fibrinogen and vWF to platelets requires exposure of the receptor, and thromboxane synthesis, nucleotide secretion, translocations of calcium ions across the membranes, and intracellular cAMP are thought to play a major role in this exposure (21, 47) . Our data make it unlikely that patient's paraprotein acts by affecting one or more of these basic events. The ability of platelets to bind fibrinogen involves platelet activation as well as the presence ofintact GPIIbIlla complexes (21) . Since the paraprotein only reacts with GPIIIa ( Fig. 3 B) and in detergent extracts GPIIb and GPIIIa from reversible heterodimer complexes (48, 49) , one could postulate that patient's paraprotein impairs fibrinogen and vWF binding to platelets by inhibiting the formation ofthe complex. Our data are not consistent with this possibility since at physiological pH more than one band can be detected on unstimulated intact platelets even in the presence of EDTA (Fig. 3 A) . Therefore, it seems reasonable to conclude that patient's paraprotein induces platelet abnormalities by sterically hindering the association of fibrinogen and vWF with the GPIIb-IIIa.
These data show that bleeding occurring in dysproteinemia may be the result of a specific interaction of monoclonal paraproteins with platelets and support the concept that the interaction of fibrinogen and/or vWF with the GPIIb-IIIa is essential for effective hemostasis.
